Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
NCT04058145 · Massachusetts General Hospital · PHASE2 · withdrawn · last registry update 2020-09-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding Withdrawn” | – | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CXCR4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-06-18Results posted on the registry: Siddhartha Ganguly, Bortezomib + Granulocyte colony-stimulating factor (G-CSF) (NCT02703779)
- 2021-06-18Also stopped (terminated): CSL Behring, Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 (NCT04091737)
- 2021-05-19Also stopped (terminated): Reproductive Medicine Associates of New Jersey, AMD3100 + Normal saline (NCT04045821)
- 2020-10-30Results posted on the registry: Children's Hospital Medical Center, Cincinnati, AMD3100 (NCT00479115)
- 2020-10-20Also stopped (terminated): Washington University School of Medicine, Fludarabine + Busulfan (NCT02750254)
- 2020-07-24Also stopped (withdrawn): Jonsson Comprehensive Cancer Center, Aldesleukin + Cellular Therapy (NCT03506802)
- 2020-04-20Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Plerixafor (NCT03226691)
- 2020-03-13Results posted on the registry: Washington University School of Medicine, Selinexor + Cladribine (NCT02416908)
- 2020-03-03Phase 3 first posted: Genetix Biotherapeutics Inc., bb1111 (NCT04293185)
- 2020-03-02Also stopped (terminated): Weill Medical College of Cornell University, Plerixafor (NCT03277209)
- 2020-02-28Results posted on the registry: Que Oncology, oral capsule of Q-122 (NCT04080297)
- 2019-12-19Also stopped (terminated): Gian Paolo Fadini, Plerixafor + Placebo (NCT02790957)
- 2019-12-17Results posted on the registry: Weill Medical College of Cornell University, bortezomib (Velcade) + cyclophosphamide (NCT01146834)
- 2019-12-11Also stopped (withdrawn): University of Maryland, Baltimore, Neupogen + Plerixafor (NCT02682953)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision